Ovarian tumors in postmenopausal breast cancer patients treated with tamoxifen

Gynecologic Oncology

Volumn 60, Issue 1, 1996, Pages 54-58

  Cohen, Ilan ^a   Beyth, Yoram ^a   Tepper, Ron ^a   Shapira, Jeremiah ^a   Zalel, Yaron ^a   Figer, Arie ^b,c   Cordoba, Mario ^a   Yigael, Dror ^a   Altaras, Marco M ^a  

^a MEIR MEDICAL CENTER   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER INCIDENCE; CLINICAL ARTICLE; CYSTADENOMA; DISEASE PREDISPOSITION; DOSE RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; OVARY CYST; OVARY TUMOR; POSTMENOPAUSE; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY;

EID: 0030032245     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.0011     Document Type: Article

References (33)

1. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy, Lancet 339, 1-15 (1992).
2. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy, Lancet 339, 71-85 (1992).
3. Hardell, L. Tamoxifen as a factor for carcinoma of corpus uteri, Lancet 3, 563 (1988).
4. Fornander, T., Cedermak, B., Mattson, A., Skoog, L., Theve, T., Askergen, J., Rutquist, L. E., Glas, U., Silfversward, C., Somell, A., Wilkins, N., and Hjalmar, M. L. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers, Lancet 21, 117-120 (1989).
5. Nouvo, M. A., Nouvo, B. J., McCaffrey, R. M., Levine, R. U., Barron, B., and Winkler, B. Endometrial polyps in postmenopausal patients receiving tamoxifen, Int. J. Gynecol. Pathol. 8, 125-131 (1989).
6. Neven, P., De Muylder, X., Van Belle, Y., Vanderick, G., and Muylder, E. Tamoxifen and the uterus and endometrium, Lancet 1, 375 (1989).
7. Malfetano, J. H. Tamoxifen-associated endometrial carcinoma in postmenopausal breast cancer patients, Gynecol Oncol. 39, 82-84 (1990).
8. Gal, D., Kopel, S., Bashevkim, M., Lebowicz, I., Lew, R., and Tancer, M. L. Oncogenic potential of tamoxifen on endometria of postmenopausal women with breast cancer: A preliminary report, Gynecol. Oncol. 42, 120-123 (1992).
9. De Muylder, X., Neven, P., and De Somer, M. Endometrial lesions in patients undergoing tamoxifen therapy, Int. J. Gynecol. Obstet. 36, 127-129 (1991).
10. Corley, D., Rowe, J., Curtis, M. T., Hogan, W. M., Noumoff, J. C., and Livolsi, V. A. Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy, Obstet. Gynecol. 79, 111-116 (1992).
11. Cohen, I., Shapira, Y., Altaras, M., Cordoba, M., and Beyth, Y. Endometrial decidual changes in a postmenopausal woman treated with tamoxifen and megestrol acetate, Br. J. Obstet. Gynaecol. 99, 773-774 (1992).
12. Altaras, M., Aviram, R., Cohen, I., Cordoba, M., Yarkoni, S., and Beyth, Y. Role of prolonged stimulation of tamoxifen therapy in the etiology of endometrial sarcomas, Gynecol. Oncol. 49, 255-258 (1993).
13. Cohen, I., Rosen, D. J. D., Shapira, J., Cordoba, M., Gilboa, S., Altaras, M., Yigael, D., and Beyth, Y. Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer, Br. J. Obstet. Gynaecol. 100, 567-570 (1993).
14. Lahti, E., Blanco, G., Kauppila, A., Apaja-Sarkkinen, M., Taskinen, P. J., and Laatikanen, T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen, Obstet. Gynecol. 81, 660-664 (1993).
15. Magriples, U., Naftolin, F., Schwartz, P. E., and Carcangiu, M. L. High grade endometrial carcinoma in tamoxifen-treated breast cancer patients, J. Clin. Oncol. 1, 485-490 (1993).
16. Seoud, M. A.-F., Johnson, J., and Weed, J. C. Gynecologic tumors in tamoxifen-treated women with breast cancer, Obstet. Gynecol. 82, 165-169 (1993).
17. Cohen, I., Rosen, D. J. D., Shapira, J., Cordoba, M., Gilboa, S., Altaras, M., Yigael, D., and Beyth, Y. Endometrial changes with tamoxifen: Comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients, Gynecol. Oncol. 52, 185-190 (1994).
18. Cohen, I., Tepper, R., Rosen, D. J. D., Shapira, J., Cordoba, M., Altaras, M., Dror, Y., and Beyth, Y. Continuous tamoxifen treatment in asymptomatic, postmenopausal breast cancer patients does not cause aggravation of endometrial pathologies, Gynecol. Oncol. 55, 138-143 (1994).
19. Clarke, M. R. Uterine malignant mixed Mullerian tumor in a patient on long-term tamoxifen therapy for breast cancer, Gynecol. Oncol. 51, 411-415 (1993).
20. van Leeuwen, F. E., Benraadt, J., Coebergh, J. W. W., Kiemeney, L. A., Gimbrere, C. H., Otter, R., Schouten, L. J., Damhuis, R. A., Bontenbal, M., Diepenhorst, F. W., et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer, Lancet 343, 448-452 (1994).
21. Fisher, B., Constantino, J. P., Redmond, C. K., Fisher, E. R., Wickerham, L., and Cronin, W. M. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14, J. Natl. Cancer Inst. 86, 527-537 (1994).
22. Gherman, R. B., Parker, M. F., and Macri, C. I. Granulosa cell tumor of the ovary associated with antecedent tamoxifen use, Obstet. Gynecol. 84, 717-719 (1994).
23. Cohen, I., Altaras, M., Lew, S., Tepper, R., Beyth, Y., and Ben-Baruch, G. Ovarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy: Case report and literature review, Gynecol. Oncol. 55, 443-447 (1994).
24. Gorodeski, G. I., Beery, R., Lunenfeld, B., and Geir, A. Tamoxifen increases plasma estrogen-binding equivalents and has an estradiol agonistic effect on histologically normal premenopausal and postmenopausal endometrium, Fertil. Steril. 57, 390-397 (1992).
25. Cramer, D. W., and Welch, W. R. Determinations of ovarian cancer risk. II. Inferences regarding pathogenesis, J. Natl. Cancer Inst. 71, 717-721 (1983).
26. Zaino, R. J., Satyaswoop, P. G., and Mortel, R. Hormonal therapy of human endometrial adenocarcinoma in a nude mouse model, Cancer Res. 45, 539-531 (1985).
27. Welsh, T. H., Xiao-Chi, J., Jones, P., Zhuang, L., and Hsueh, A. J. Disparate effects of triphenylethylene antiestrogens on estrogen and progestin biosynthesis by cultured rat granulosa cells, Endocrinology 115, 1275-1282 (1984).
28. Tucker, M. J., Adam, H. K., and Patterson, H. S. Tamoxifen, in Safety testing in new drugs: Laboratory predictions and clinical performance (D. R. Laurence, A. E. H. McLean, and M. Weatherall, Eds.), Harcourt Brace Jovanovich, New York, pp. 125-161 (1984).
29. Higgins, R. V., van Nagell, J. R., Jr., Donaldson, E. S., et al. Transvaginal sonography as a screening method for ovarian cancer, Gynecol. Oncol. 34, 402-406 (1989).
30. van Nagell, J. R., Jr., Higgins, R. V., Donaldson, H. H. G., Powell, D. E., Pavlik, E. J., Woods, C. H., and Thompson, E. A. TVS as a screening method for ovarian cancer: A report of the first 1000 cases screened, Cancer 65, 573-577 (1990).
31. Campbell, S., Bhan, V., Roytson, P., Whitehead, M. I., and Collins, W. P. Transabdominal ultrasound screening for early ovarian cancer, Br. Med. J. 299, 1363-1367 (1989).
32. Bourne, T. H., Whitehead, M. A., Campbell, S., Roytson, P., Bhan, V., and Collins, W. P. Ultrasound screening for familial ovarian cancer, Gynecol. Oncol. 43, 92-97 (1991).
33. deWaard, F. In Uterine corpus in cancer epidemiology and prevention (D. Schottenfield and J. F. Fraumeni, Eds.), Saunders, Philadelphia, pp. 901-908 (1982).